Lantz O - Search Results

1

IL-2 receptors on circulating natural killer cells and T lymphocytes. Similarity in number and affinity but difference in transmission of the proliferation signal.

Ben Aribia MH, Moiré N, Métivier D, Vaquero C, Lantz O, Olive D, Charpentier B, Senik A. Ben Aribia MH, et al. Among authors: lantz o. J Immunol. 1989 Jan 15;142(2):490-9. J Immunol. 1989. PMID: 2783438

2

Allogenic recognition in 1992.

Lantz O, Alard P, Charpentier B. Lantz O, et al. Biomed Pharmacother. 1992;46(2-3):85-90. doi: 10.1016/0753-3322(92)90278-f. Biomed Pharmacother. 1992. PMID: 1421042

3

Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome.

Charpentier B, Hiesse C, Lantz O, Ferran C, Stephens S, O'Shaugnessy D, Bodmer M, Benoit G, Bach JF, Chatenoud L. Charpentier B, et al. Among authors: lantz o, o shaugnessy d. Transplantation. 1992 Dec;54(6):997-1002. doi: 10.1097/00007890-199212000-00011. Transplantation. 1992. PMID: 1465794 Clinical Trial.

4

Decreased lymphokine-activated killer cells in kidney transplant recipients. Correlation with a diminished number of CD3-/NKH1+ cells.

Alard P, Lantz O, Ramirez A, Perrot JY, Chavanel G, Fries D, Charpentier B, Senik A. Alard P, et al. Among authors: lantz o. Transplantation. 1990 Aug;50(2):250-7. doi: 10.1097/00007890-199008000-00016. Transplantation. 1990. PMID: 1696407

5

[Acute clinical syndrome associated with OKT3 administration. Prevention by single injection of an anti-human TNF monoclonal antibody].

Charpentier B, Hiesse C, Ferran C, Lantz O, Fries D, Bach JF, Chatenoud L. Charpentier B, et al. Among authors: lantz o. Presse Med. 1991 Nov 27;20(40):2009-11. Presse Med. 1991. PMID: 1837113 Clinical Trial. French.

6

[Treatment with Lo-Tact-1, a monoclonal antibody to the interleukin-2 receptor, in kidney transplantation].

Hiesse C, Lantz O, Kriaa F, Noury J, Fries D, Charpentier B, Bazin H. Hiesse C, et al. Among authors: lantz o. Presse Med. 1991 Nov 27;20(40):2036-8. Presse Med. 1991. PMID: 1837120 Clinical Trial. French.

7

[Arterial stenosis in the renal graft. Spontaneous evolution in 40 cases].

Deglise-Favre A, Hiesse C, Lantz O, Moukarzel M, Bensadoun H, Benoît G, Charpentier B, Fries D. Deglise-Favre A, et al. Among authors: lantz o. Presse Med. 1991 Nov 27;20(40):2048-9. Presse Med. 1991. PMID: 1837124 French.

8

EBV cell-lines (LCL) and E- cells as stimulator cells for limiting dilution analysis (LDA) of alloreactive IL-2-secreting cells (IL-2-SC) and cytotoxic precursors (CTLp). Comparison of their stimulator capacity and ability to generate specific alloreactivity.

Lantz O, Alard P, Chavanel G, Fries D, Senik A, Charpentier B. Lantz O, et al. J Immunol Methods. 1991 Mar 1;137(1):121-32. doi: 10.1016/0022-1759(91)90401-z. J Immunol Methods. 1991. PMID: 1849154

9

Persistence of donor-specific IL-2-secreting cells and cytotoxic T lymphocyte precursors in human kidney transplant recipients evidenced by limiting dilution analysis.

Lantz O, Alard P, Ben Aribia MH, Chavanel G, Fries D, Senik A, Charpentier B. Lantz O, et al. J Immunol. 1990 May 15;144(10):3748-55. J Immunol. 1990. PMID: 2332630

10

Suppressive phenomena and absence of clonal deletion evidenced by limiting dilution analysis (LDA) of donor-specific IL2 secreting cells (IL2 SC) and cytotoxic precursors (CTLp).

Lantz O, Alard P, Ben Aribia H, Fries D, Senik A, Charpentier B. Lantz O, et al. Transplant Proc. 1989 Feb;21(1 Pt 1):367-8. Transplant Proc. 1989. PMID: 2650150 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

255 results

Search Page